Head and Neck Cancer

Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy in High-Risk Resected Oral Cavity Squamous Cell Carcinoma: A Multi-Institutional Collaboration

2005-2015

Adjuvant chemoradiation (CRT), with high-dose cisplatin remains standard treatment for oral cavity squamous cell carcinoma (OCSCC) with high-risk pathologic features. We evaluated outcomes associated with different cisplatin dosing and schedules, concurrent with radiation (RT), and the effect of cumulative dosing of cisplatin.

Disease Free Survival By Does Of Concurrent Cisplatin

2005-2015

CDDP, Cisplatin; DFS, Disease free survival.

Based on our multi-institution collaborative cohort of retrospective data, we found that a dose of ≥200 mg/m² of cisplatin had a significant impact on DFS in high-risk resected OCSCC. Our study is one of the largest of its kind and one of the first to report on the association between cumulative dosing and survival outcomes in the adjuvant setting. Cisplatin administration schedule (weekly vs. every 3 weeks) was not associated with significant effect on DFS. Our study also showed that the presence of PNI was associated with worse survival outcomes. A randomized controlled trial would be required to better define the effects of cumulative dose on survival outcomes in the adjuvant setting.

References

Babar A, Woody NM, Ghanem AI, Tsai J, Dunlap NE, Schymick M, Liu HY, Burkey BB, Lamarre ED, Ku JA, Scharpf J, Prendes BL, Joshi NP, Caudell JJ, Siddiqui F, Porceddu SV, Lee N, Schwartzman L, Koyfman SA, Adelstein DJ, Geiger JL. Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. Curr Oncol. 2021 Jun 30;28(4):2409-2419.